SCHEMBL3407963

SCHEMBL3407963

COc1ccc(-c2csc(Nc3ncccc3C)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 1.00
NPC1 O15118 12/20 1.00
GAA P10253 9/20 1.00
SMN1; SMN2 Q16637 7/20 1.00
NFKB1 P19838 6/20 1.00
NFKB2 Q00653 6/20 1.00
RELA Q04206 6/20 1.00
KMT2A Q03164 12/20 0.75
MEN1 O00255 11/20 0.75
MAPT P10636 9/20 0.74
ALDH1A1 P00352 5/20 0.73
HTT P42858 2/20 0.67
MAPK1 P28482 1/20 0.67
POLB P06746 3/20 0.66
KDM4E B2RXH2 2/20 0.66
ALOX12 P18054 2/20 0.66
BLM P54132 1/20 0.66
LMNA P02545 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
TDP1 Q9NUW8 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29858646 1.00 RAB9A (1.00) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL16137473 0.87 RAB9A (0.82) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL16137398 0.86 RAB9A (0.85) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL24358063 0.86 NPC1 (0.75) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL29601192 0.86 NPC1 (0.75) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL838280 0.85 RAB9A (0.87) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL18029503 0.85 RAB9A (1.00) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL28155509 0.81 RAB9A (0.69) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL12296217 0.80 RAB9A (1.00) RAB9ANPC1GAASMN1; SMN2NFKB1
SCHEMBL16137396 0.80 NPC1 (0.79) RAB9ANPC1GAASMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
CN-101990433-A Compounds that enhance atoh-1 expression BRIGHAM & WOMENS HOSPITAL 2011-03-23 CN claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2025-03-27 US disclosed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-11963968-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-04-23 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 RAB9A 1434/4885NPC1 1607/4885GAA 4549/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 RAB9A 2455/4885NPC1 1630/4885GAA 4425/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 RAB9A 4314/4885NPC1 1011/4885GAA 4348/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 RAB9A 3020/4885NPC1 1656/4885GAA 4768/4885
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS HES1, NOTCH1, NOTCH4 RAB9A 3020/4885NPC1 1656/4885GAA 4768/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 RAB9A 4168/4885NPC1 966/4885GAA 4215/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP RAB9A 3293/4885NPC1 1018/4885GAA 3305/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 RAB9A 1434/4885NPC1 1607/4885GAA 4549/4885
US-11963968-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 RAB9A 1434/4885NPC1 1607/4885GAA 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.